Literature DB >> 8382246

Defective T cell receptor-mediated signaling and differential induction of T cell functions by murine AIDS virus superantigen.

O Kanagawa1, M E Wiebenga, B A Vaupel.   

Abstract

A B cell line, B6-1710, expressing murine AIDS virus superantigen stimulates T cell hybridomas derived from a Ld-specific CTL clone to produce IL-2 regardless of their CD4/CD8 phenotype. However, B6-1710 cell did not stimulate the original CTL clone, L3, in either proliferation or cytolytic assays. Both B6-1710 and Ld+ P815 cells stimulated a significant Ca2+ influx in the T cell hybridomas. In contrast, only P815 stimulated tyrosine phosphorylation of a 19-kDa protein in the T cell hybridoma. The addition of the nonspecific protein kinase C activator PMA restored the proliferative response of L3 cells to B6-1710. PMA did not induce the lysis of B6-1710 cells by L3. These results suggest that murine AIDS virus encoded superantigen elicits a TCR-mediated signal different from that caused by nominal Ag. This different signaling by viral superantigen may be important for the development of viral pathogenesis in vivo.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8382246

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  LP-BM5 virus-infected mice produce activating autoantibodies to the AMPA receptor.

Authors:  E Koustova; Y Sei; L Fossom; M L Wei; P N Usherwood; N B Keele; M A Rogawski; A S Basile
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

Review 2.  Cells and cytokines in the pathogenesis of MAIDS, a retrovirus-induced immunodeficiency syndrome of mice.

Authors:  H C Morse; N Giese; R Morawetz; Y Tang; R Gazzinelli; W K Kim; S Chattopadhyay; J W Hartley
Journal:  Springer Semin Immunopathol       Date:  1995

3.  MR1 uses an endocytic pathway to activate mucosal-associated invariant T cells.

Authors:  Shouxiong Huang; Susan Gilfillan; Sojung Kim; Bruce Thompson; Xiaoli Wang; Andrea J Sant; Daved H Fremont; Olivier Lantz; Ted H Hansen
Journal:  J Exp Med       Date:  2008-04-28       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.